Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically demonstrated prostatic adenocarcinoma.
Patients never previously treated with hormonal therapy for prostate cancer.
Patients eligible for hormonal therapy after initial consultation (alone or in combination with curative treatment).
Patients agreeing to the collection of personal health data for the purposes of the study.
Patients with locally advanced or metastatic prostatic cancer tumours or a biological recurrence after curative treatment.
You may not be if
Patients participating in a clinical study involving prostate cancer at the time of inclusion in the investigation.
Patients having received or currently receiving hormonal treatment for prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors).
Clareo Health | Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
